For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() Elevance Health, Inc.ELV US · Health Care · USD Current price$390.16as of Nov 20, 2026 Summary
Analyst consensusStrong Buy 3Buy 13Hold 621 analysts 3-year price (USD)Factor profileMulti-factor score 66 / 100 Market data
Business descriptionSecond-largest U.S. health plan provider (formerly Anthem), serving over 45M members across commercial, Medicare, Medicaid and Federal plans, with Blue Cross Blue Shield licences in many states. Sub-industry: Managed Health Care; S&P 500, Large-Cap Value. Competitive moatScale (about 45M members) supports provider-network pricing, and the BCBS brand/licences are a durable edge with national commercial group clients. Moderate Medicare Advantage exposure (4.9% of medical membership, about 23% of consolidated revenue from Medicare programs) limits MA-specific cost risk versus peers. Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Nov 13, 2026
Current price: $390.16 · Nov 20, 2026· USD
CFRA Ratingbuy
TBI Multi Score66
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: ELVBusiness description
Second-largest U.S. health plan provider (formerly Anthem), serving over 45M members across commercial, Medicare, Medicaid and Federal plans, with Blue Cross Blue Shield licences in many states. Sub-industry: Managed Health Care; S&P 500, Large-Cap Value.
Competitive moat
Scale (about 45M members) supports provider-network pricing, and the BCBS brand/licences are a durable edge with national commercial group clients. Moderate Medicare Advantage exposure (4.9% of medical membership, about 23% of consolidated revenue from Medicare programs) limits MA-specific cost risk versus peers.
Recent developments
- Q3 2026 (10/21/2026): EPS beat despite membership losses; 2026 adjusted EPS guide raised to at least USD 29.00 (from 27.00), operating cash flow to at least USD 6.5B. 2027: at least 12% adjusted EPS growth off a base of at least USD 26.75; benefit expense ratio guided about 90.2%.
- 2026 framed as a repositioning year: Medicaid at trough (-1.75% margin), exit from Washington D.C. Medicaid and more exits signaled; ACA year-end membership about 1.2M (vs 1.0M expected). 2027 Medicaid margin framing deferred to Q4 results (January 2027).
- CMS compliance overhang resolved in July without sanctions (USD 935M accrual in Q1, USD 342M paid in Q2).
- Sector read: beneficiary of possible No Surprises Act IDR reform. See Managed Health Care Q3 2026 Earnings & Post-Midterm Policy.
Investment risks / red flags
- Medicaid funding and OBBBA work requirements (by 12/31/2026); ACA enhanced subsidy expiry shifting the risk pool.
- Benefit expense ratio elevated (2025: 90.0%, +150 bps); utilization spikes.
- Legislative proposals targeting private plans and PBMs; premium revenue and membership declines expected.
Market Data
Source: mkts.io · Nov 20, 2026, 14:01 UTC
Key Metrics
P/E (TTM)16.57
P/E (Fwd)12.88
Dividend1.76%
Beta0.63
52W High$450.69
52W Low$274.84
Analyst Consensus
3
13
6
Strong Buy3Buy13Hold621 analysts
Consensus Target$482.38
+23.6% upside
Calendar Events
Next EarningsJan 28, 2027
Ex-DividendDec 4, 2026
Dividend DateDec 18, 2026
Financials
Revenue$201.83B
Rev Growth1.40%
Earnings Growth17.90%
Gross Margin26.43%
Op Margin3.98%
Profit Margin2.55%
EBITDA$8.71B
ROA4.00%
ROE11.48%
Rev/Share$923.29
Total Cash$37.85B
Total Debt$30.76B
D/E Ratio68.66
Free Cash Flow$7.99B
Op Cash Flow$7.60B
Current Ratio1.47
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 2.07 | $49.14B |
| +1q | 12.32 | $50.06B |
| 0y | 29.14 | $198.85B |
| +1y | 30.29 | $203.75B |
Earnings
Quarterly EPS
4Q2025
Est: 3.093.33Beat
1Q2026
Est: 10.8112.58Beat
2Q2026
Est: 6.217.45Beat
3Q2026
Est: 4.696.99Beat
Annual
2022
Rev $155.66BEarn $6.03B
2023
Rev $170.21BEarn $5.99B
2024
Rev $175.20BEarn $5.98B
2025
Rev $197.58BEarn $5.66B
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Oct 27, 2026 | Wells Fargo | main | Overweight |
| Oct 23, 2026 | TD Cowen | main | Buy |
| Oct 22, 2026 | UBS | main | Buy |
| Oct 22, 2026 | Guggenheim | main | Buy |
| Oct 22, 2026 | Morgan Stanley | main | Equal-Weight |
| Oct 22, 2026 | RBC Capital | main | Sector Perform |
